Acrivon Therapeutics, Inc. (ACRV)
1.75
+0.03
(+1.74%)
USD |
NASDAQ |
Oct 15, 15:58
Acrivon Therapeutics Net Income (Quarterly) : -17.96M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -17.96M |
| March 31, 2026 | -19.04M |
| December 31, 2025 | -18.98M |
| September 30, 2025 | -18.23M |
| June 30, 2025 | -21.01M |
| March 31, 2025 | -19.68M |
| December 31, 2024 | -22.83M |
| September 30, 2024 | -22.44M |
| June 30, 2024 | -18.80M |
| March 31, 2024 | -16.49M |
| Date | Value |
|---|---|
| December 31, 2023 | -19.25M |
| September 30, 2023 | -14.47M |
| June 30, 2023 | -13.91M |
| March 31, 2023 | -12.76M |
| December 31, 2022 | -8.929M |
| September 30, 2022 | -9.198M |
| June 30, 2022 | -5.82M |
| March 31, 2022 | -7.22M |
| December 31, 2021 | -4.343M |
| September 30, 2021 | -2.44M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 17.96M |
| EPS Diluted (Quarterly) | -0.4293 |
| Enterprise Value | -14.15M |
| Earnings Yield | -107.7% |
| Normalized Earnings Yield | -107.71 |